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gently needed, hepatocellular carcinoma (HCC) exhibits
intriguing opportunities for oncolytic virotherapy. Here we
report the rational generation of a novel herpes simplex virus
type 1 (HSV-1)-based oncolytic vector for targeting HCC,
named Ld0-GFP, which was derived from oncolytic ICP0-null
virus (d0-GFP), had a fusogenic phenotype, and was a novel
killer against HCC as well as other types of cancer cells.
Compared with d0-GFP, Ld0-GFP exhibited superior cancer
cell-killing ability in vitro and in vivo. Ld0-GFP targets a broad
spectrum of HCC cells and can result in significantly enhanced
immunogenic tumor cell death. Intratumoral and intravenous
injections of Ld0-GFP showed effective antitumor capabilities
in multiple tumor models, leading to increased survival. We
speculated that more active cell-killing capability of oncolytic
virus and enhanced immunogenic cell death may lead to better
tumor regression. Additionally, Ld0-GFP had an improved
safety profile, showing reduced neurovirulence and systemic
toxicity. Ld0-GFP virotherapy could offer a potentially less
toxic, more effective option for both local and systemic treat-
ment of HCC. This approach also provides novel insights to-
ward ongoing efforts to develop an optimal oncolytic vector
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Hepatocellular carcinoma (HCC) is the sixth most common malig-
nancy and the third most common cause of cancer-related death
worldwide.1,2 Although curative treatments such as liver resection,
liver transplantation, and local ablation have improved the outcome
in early stage HCC, most patients are not considered as candidates
for these therapies because of an advanced tumor stage or inadequate
liver function at the time of diagnosis.3 This limits their treatment to
fewer options, such as target-oriented chemotherapeutic methods
and inhibitor drugs. HCC patients generally present with poor prog-
nosis; no effective treatment is available for most patients, and the 5-
year relative survival rate for patients with advanced stage HCC is
only below 11%.4 Therefore, a more innovative and effective treat-Molecular The
This is an open access article under the CC BY-NC-ment for dealing with advanced stage HCC is required to improve pa-
tient survival.
In this regard, oncolytic virotherapy offers a promising therapeutic
option for treating advanced stage HCC, with tremendous advan-
tages, such as tumor selectivity, safety, effectiveness, immunomodula-
tion, and fewer adverse effects.5,6 The lead oncolytic virus (OV) in
HCC clinical trials, JX-594, has demonstrated evidence of clinical
benefit and been granted orphan drug status by the US Food and
Drug Administration (FDA).7 In 2015, OV T-VEC had shown ther-
apeutic benefit against melanoma and become the first FDA-
approved oncolytic virotherapy to treat advanced melanoma.8 To
date, a number of OVs, including adenovirus, reovirus, measles, her-
pes simplex virus, enterovirus, Newcastle disease virus, and vaccinia,
have shown single-agent clinical activity and evidence of clinical syn-
ergy with immune checkpoint blockade.9,10
Among the OVs, human herpes simplex virus 1 (HSV-1) is one of the
agents having several features that meet the requirements for onco-
lytic virotherapy, and various forms of genetically modified vectors
have been developed for cancer therapy.5,11 The most advanced can-
didates, including T-Vec, G207, 1716, G47D, and HF10, have been
evaluated in clinical trials, stating evidence of benefits in treating
various types of advanced cancer, such as melanoma, glioma, head
and neck cancer, and breast cancer.12,13 Some efforts have been
made to test the antitumor activity of HSV-1-based OVs in preclinical
models of HCC, with some evidence of antitumor efficacy.14–19 Arapy: Oncolytics Vol. 15 December 2019 ª 2019 The Author(s). 153
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Development of an ICP0 Deletion HSV-1
Virus Targeting HCC
(A) Schematic diagram of developing Ld0-GFP in HCC
cell lines, including repeated infection, fusogenic plaque
selection, and assessment of viral replication and cell
killing. (B) Route map for generating fusogenic d0-GFP
progenies and assessing their viral replication efficiency
and cell-killing ability. (C) Cell viability was measured in
various infected QGY7703 cell lines at 72 h after virus
infection. (D) Cell viability was measured in various in-
fected L-02 cell lines at 72 h after virus infection. (E) IC50
was calculated in various infected QGY7703 cell lines. (F)
IC50 was calculated in various infected L-02 cell lines.
Molecular Therapy: Oncolyticsnumber of HSV-1-based oncolytic vectors were designed to target
HCC using tissue-specific promoters to drive the expression of an
essential viral gene,20–22 however, few efforts have concentrated on
engineering OV cellular specificity and enhancing its antitumor po-
tency against HCC.23 New approaches to the treatment of HCC are
being continuously investigated to facilitate the development of treat-
ments with superior efficacy and lower toxicity.
d0-GFP is an ICP0-null, replication-selective HSV-1 virus, as previ-
ously described.24,25 ICP0-null HSV-1 exploit interferon (IFN)-
signaling defects in a number of different tumor types. ICP0 is
required to stimulate the translation of viral mRNA in quiescent cells,154 Molecular Therapy: Oncolytics Vol. 15 December 2019and it plays a key role in blocking IFN-induced
inhibition of viral infection,25 so ICP0-null
HSV-1 replicates more efficiently in cancer cells
than in normal cells. Here we introduced a
rational design and generated OV Ld0-GFP
for targeting HCC, which was selected and ob-
tained by repeated passage of d0-GFP in HCC
cells and has superior oncolytic activity and tu-
mor selectivity. Ld0-GFP enhances the onco-
lytic activity by forming large syncytia, and it in-
duces immunogenic cell death in a variety of
HCC cell types. In this study, the oncolytic ac-
tivity of Ld0-GFP against HCC was investigated
both in vitro and in vivo, and the safety profile of
Ld0-GFP was investigated in immunocompe-
tent mice. Such a safe and potent OV seems to
be a good choice as a treatment for patients
with HCC. These results add value to our un-
derstanding of the mechanisms of action of tu-
mor-specific oncolytic vectors.
RESULTS
Development of a Novel OV against HCC
To generate the oncolytic HSV-1 vectors for
HCC, we first repeated passage of d0-GFP in
Hep3B, QGY7703, and SMMC7721 cell lines,
and we screened the fusogenic d0-GFP proge-
nies for targeting HCC (Figure 1A). Thescreening strategy is depicted in Figure 1B. For every round of d0-
GFP passage, the cells were infected with viruses at an MOI of 1
and then harvested at 72 h post-infection for subsequent re-infection.
After seven rounds of repeated infection, the d0-GFP progenies,
which can form fusogenic plaque, were subjected to single-plaque pu-
rification, and those that can form syncytia like plaque were selected
for preliminary assessment.
To obtain the most potent OVs for targeting HCC, ten fusogenic d0-
GFP progenies were picked out and evaluated by testing their replica-
tion difference in U-2 OS cells and cell-killing ability on both HCC
cell lines (QGY7703) and the hepatic normal cell line (L-02). OV,
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Figure 2. Characteristics of HCC Targeting
Oncolytic Virus, Ld0-GFP
(A) Plaque assays of Ld0-GFP and d0-GFP virus on
SMMC7721 monolayers. 200 PFU per dish for each virus
was used in this assay. (B) 30 random plaques were
selected from each virus-infected dish, and the average
area of individual plaque was calculated. In addition, the
fold change between the average size of Ld0-GFP pla-
ques and d0-GFP plaques is shown. Data are shown as
means ±SEM. (C) Viral replication assays were performed
on SMMC7721 cells at an MOI of 0.05 PFU/cell. Ld0-GFP
and d0-GFP replication patterns were monitored at 24 or
48 h after virus infection. Red arrows indicate virus-in-
fected cells and regular plaques. Orange arrows indicate
virus-infected cells and fusogenic plaques. Cells were
observed using Operetta High Content Imaging System
(PerkinElmer), with a 10 objective. (D) Replication as-
says were performed on U-2 OS cells at different time
points after virus infection. (E) Cell-killing assays were
performed on U-2 OS cells at different time points after
virus infection. Graphs represent pooled data from three
independent experiments. Values are the means of three
independent experiments; data are shown as means ±
SEM. Data were analyzed by unpaired two-tailed Stu-
dent’s t tests.
www.moleculartherapy.orgwhich had the greatest replication efficiency and relatively higher tu-
mor-killing selectivity, was selected for further assessment. It showed
that d0-GFP-7 had highest replication efficiency among those fuso-
genic d0-GFP progenies, and it had almost equivalent replication ef-
ficiency to d0-GFP (Figure S1). After the comparative evaluation of
their cell-killing ability in HCC cell lines (QGY7703) and the hepatic
normal cell line (L-02), compared to d0-GFP, we discovered d0-GFP-
7 (named Ld0-GFP) with good tumor selectivity, which exhibited
high lytic capacity in HCC cells but low lytic capacity in liver normal
cells (Figures 1C and 1D). Our data showed that the dose required to
kill 50% of cells (IC50) of Ld0-GFP was at least 26-fold lower than
that of d0-GFP inQGY7703 cells, but the IC50 of Ld0-GFP was at least
2.5-fold higher than that of d0-GFP in L-02 cells (Figures 1E and 1F),
suggesting Ld0-GFP was a superior candidate as a selective killer
against HCC.
To assess the oncolytic characteristics of Ld0-GFP, we first compared
the plaque size between d0-GFP and Ld0-GFP in SMMC7721 cells.Molecular TheThe plaque size of Ld0-GFP was significantly
larger than that of d0-GFP due to the syncy-
tia-forming ability of Ld0-GFP (Figures 2A
and 2B). During the infection, Ld0-GFP could
induce SMMC7721 cancer cell fusion so as to
exhibit higher cell-killing activity, and the
obvious cell death was only observed at 24 h
post-infection of Ld0-GFP (Figure 2C). U-2
OS cells are widely accepted as a common cell
model for studying HSV-1 replication and yield.
After ten rounds of viral propagation in U-2 OScells at an MOI of 0.005, Ld0-GFP progenies were syncytial and ho-
mogeneous (Figure S2).
Next, we evaluated the replication efficiency and oncolytic potency of
Ld0-GFP and d0-GFP in U-2 OS cells. As shown in Figures 2D and
2E, Ld0-GFP had better viral yields than d0-GFP only at 24 h post-
infection, and later Ld0-GFP and d0-GFP showed similar replication
efficiency. However, Ld0-GFP induced significantly higher cell killing
than d0-GFP at 24, 48, and 72 h post-infection. Although Ld0-GFP
and d0-GFP showed comparable replication efficiency, the oncolytic
potency of Ld0-GFP was significantly enhanced in U-2 OS cells, sug-
gesting that the oncolysis-induced cell fusion may contribute to the
enhanced cell-killing capability of Ld0-GFP against HCC at late stage.
Ld0-GFP Targets a Broad Spectrum of HCC Cancer Cells with
Improved Oncolytic Activity
To explore the oncolytic efficacy of Ld0-GFP in vitro, we first
compared the cell-killing effects of d0-GFP and Ld0-GFP virusesrapy: Oncolytics Vol. 15 December 2019 155
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that we tested, Ld0-GFP showed markedly enhanced oncolysis
compared to d0-GFP (Figure S3; Figure 3A). As shown in Figure 3B,
the IC50 of Ld0-GFP was at least 5-fold lower than that of d0-GFP
in HepG2, Huh7, QGY7703, MHHC97H, and Hep3B cells, and the
IC50 of Ld0-GFP was at least 2-fold lower than that of d0-GFP in
the remaining HCC cell lines, besides PLC/PRF/5 in which the IC50
of Ld0-GFP was only 1.41-fold lower than that of d0-GFP. Our
data showed Ld0-GFP exhibited increased cell-killing ability not
only in high permissive HCC cell lines (HCCLM3, PLC/PRF/5, and
Hep3B) but also in less permissive HCC cell lines (SK-HEP-1,
BEL7404, and MHHC97H). All these data suggested Ld0-GFP
showed superior antitumor capabilities and targets a broad spectrum
of HCC cancer cells. Moreover, we tested the in vitro activity of the
viruses in the mouse H22 cells, and the IC50 of Ld0-GFP was at least
2-fold higher than that of d0-GFP irrespective of the relatively low
permissivity of mouse cells to HSV-1 (Figure S4). Additionally, our
data showed Ld0-GFP exhibited increased cell-killing ability in
non-HCC tumor cells, such as H1299 and HCT116 cells (Figures
S5A–S5C).
Ld0-GFP Induces Strong Immunogenic Cell Death in HCC Cell
Lines
To explore the cell death types involved in Ld0-GFP-induced oncol-
ysis, we examined the apoptosis markers after treatment with Ld0-
GFP or d0-GFP. Annexin V/propidium iodide (PI)-labeled fluores-
cence-activated cell sorting (FACS) analyses showed significant upre-
gulation of annexin V staining at 24 h after viral infection in four
HCC cell lines (Figure 4A). Ld0-GFP induced stronger cell apoptosis
than d0-GFP in HCC cell lines, and this induction of cell apoptosis
was in a dose-related fashion (Figure 4B). However, due to the cell
destruction ability of OVs, the cells may be directly destructed
when exposed to a high dosage of virus infection, thus the percentage
of cell apoptosis was relatively lower in some HCC cells after treat-
ment with OVs at an MOI of 10.
Similar results were obtained when we determined the late apoptosis
or necrosis at 24 h after viral infection in four HCC cell lines (Fig-
ure S6). To determine the immunogenic profile of virus-infected
HCC cell lines, HCC cell lines were infected with Ld0-GFP or d0-
GFP at various MOIs. The supernatants harvested from the infected
cells were analyzed for expression of the immunogenic cell death
(ICD) determinants (extracellular ATP and HMGB1) at 24 h after
viral infection. The secreted ATP and HMGB1 were evidently upre-
gulated in the supernatants of Ld0-GFP-infected HCC cells compared
to d0-GFP-infected HCC cells, and this induction of secreted ATP
and HMGB1 was in a dose-related fashion (Figures 4C and 4D).
All these data suggested Ld0-GFP induced stronger immunogenic
cell death by activating the ICD pathway compared to d0-GFP.26Figure 3. Oncolytic Effect of Ld0-GFP in HCC Cell Lines
(A) Cell viability assays were performed on a panel of HCC cell lines at 72 h after Ld0-GFP
in various infected HCC cell lines.Safety Profile of Ld0-GFP in BALB/c Mice
To evaluate the safety and potential toxicity of Ld0-GFP, we estab-
lished two different toxicity evaluation models, including the murine
lethal challenge model and systemic challenge model (Figures 5A and
6A). For the murine lethal challenge model, the BALB/c mice were
challenged through a single intracerebral inoculation of Ld0-GFP
or d0-GFP (1  105 plaque-forming units [PFU] per dose). Mice
were challenged with HSV-1 wild-type strain KOS (1  104 PFU
per dose) as a parallel positive control.
It was observed that 90% of mice survived in the Ld0-GFP-challenged
group and in the d0-GFP-challenged group compared to the KOS-
challenged group, while all mice died in the KOS-challenged group
(Figure 5B). The results showed that Ld0-GFP and d0-GFP exhibited
comparably reduced neurovirulence in vivo. On days 1, 5, 15, and 30,
the histological analysis of whole brains of virus-injected mice and
vehicle-injected mice was performed by H&E staining. Obvious
pathological abnormality was observed in the brains of KOS-injected
mice, but not in those of the Ld0-GFP-injected mice and d0-GFP-in-
jected mice (Figure 5C). It was observed that the brain tissue around
the KOS-injected site was severely injured compared to that around
the Ld0-GFP- or d0-GFP-injected site, which led to the deaths of
KOS-injected mice within 1 week. Although slight injury was found
around the injection route of brain tissue both in d0-GFP-injected
mice and Ld0-GFP-injected mice on day 5 post-injection, all mice
finally survived and recovered to normal.
Moreover, we established a systemic challenge model to evaluate the
toxicity of Ld0-GFP in mice through a single high dose of intravenous
injection of virus (5  107 PFU per dose) or PBS (vehicle). A signif-
icant difference in body weight between the Ld0-GFP-injected group
and the KOS-injected group was observed, and there was no differ-
ence in body weight between the Ld0-GFP-injected group and the
d0-GFP-injected group during the course of the study (Figure 6B).
On days 1, 5, 7, and 30, the histological analysis of vital tissues of vi-
rus-injected mice and vehicle-injected mice (n = 2 for each group),
including heart, liver, spleen, lung, and kidney, was performed by
H&E staining. No obvious pathological abnormality was observed
in hearts, livers, spleens, and kidneys of virus-injected mice (Fig-
ure 6C). Acute lung injury was observed in KOS-injected mice, but
not in Ld0-GFP-injected mice and d0-GFP-injected mice (Figure 6C).
All the evidence supports the conclusion that Ld0-GFP is relatively
safe in mice.
Preclinical Evaluation of Ld0-GFP in HCC Mouse Models
To further evaluate the antitumor potential of Ld0-GFP in vivo, we
established three different preclinical tumor models, including the
subcutaneous xenograft nude mice model bearing Huh7 and
Hep3B HCC (Figure 7A) and the syngeneic HCC mouse modelor d0-GFP infection (MOI = 0.001–10 PFU/cell), respectively. (B) IC50 was calculated
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ure 8A). For subcutaneous xenograft models, after the implanted tu-
mor volume reached 100 mm3, mice in each model were randomized
to receive three doses of intratumoral injection of Ld0-GFP or d0-
GFP (5 106 PFU per dose). Mice received PBS (vehicle) as a parallel
negative control. It was observed that tumor growth was significantly
inhibited in the Ld0-GFP-treated group compared to the d0-GFP-
treated or vehicle-treated group (Figures 7B and 7D). The results
showed that Ld0-GFP exhibited excellent therapeutic efficacy in
HCC xenografted immunodeficient mice. Additionally, no obvious
toxicity was observed in the virus-treated group during the treatment.
However, obvious body weight change was observed in vehicle-
treated groups, possibly due to the adverse effect of rapid tumor
growth on nude mice (Figures 7C and 7E).
For the syngeneic HCC mouse model, after the implanted tumor
volume reached 100 mm3, mice were randomized to receive three
doses of intravenous injection of Ld0-GFP or d0-GFP (1  107
PFU per dose). Mice received PBS (vehicle) as a parallel negative
control. It was observed that tumor growth was significantly inhibited
in the Ld0-GFP-treated group compared to the d0-GFP-treated or
vehicle-treated group (Figure 8B), and prolonged survival time was
observed in the Ld0-GFP-treated group (Figure 8C). Since mice
from the vehicle-treated group started to die on day 30 after virus
treatment, we thereafter followed up the long-term survival.
Ld0-GFP therapy induced robust tumor eradication and durable
cures without relapse in 62.5% of the mice implanted with H22 tu-
mors during a 150-day follow-up (Figure 8C), showing higher efficacy
compared to d0-GFP therapy (durable cures in 37.5% of the mice).
Moreover, we established orthotopic HCC mice bearing mouse
H22 HCC in situ to evaluate the oncolytic efficacy of Ld0-GFP in
the context of the liver microenvironment through three doses of
intravenous injection of virus (1  107 PFU per dose); consistent
with the previous subcutaneous xenograft models, remarkedly
reduced tumor size and prolonged survival were observed in the
Ld0-GFP-treated group (Figure 8D). As shown in Figure 8E, the liver
tumor sizes were significantly reduced in the Ld0-GFP-treated group
compared to the d0-GFP-treated at 10 or 20 days after the initial
treatment.
DISCUSSION
Treatment options and their outcomes in HCC have not changed
significantly in decades. Sorafenib has been the standard therapy
for patients with unresectable HCC since 2007; however, the clinical
efficacy of sorafenib is still unsatisfactory, and only 2–3 months of life
was prolonged in patients with advanced HCC.27 Lenvatinib has beenFigure 4. Ld0-GFP Can Induce Stronger Immunogenic Cell Death in HCC Cell L
(A) Determination of levels of early apoptosis in four HCC cell lines left uninfected or infe
annexin-V/PI-labeled flow cytometry. (B) Graphs represent pooled data from three indep
HCC cell lines left untreated or infected with Ld0-GFP or d0-GFP at MOIs of 0.1, 1, and
four HCC cell lines left untreated or infected with Ld0-GFP or d0-GFP at MOIs of 0.1, 1
experiments. Values are the means of three independent experiments; data are showndemonstrated to be non-inferior to sorafenib in overall survival in un-
treated advanced HCC.28 Recently, a combination therapy of lenvati-
nib and anti-PD-1 inhibitor has been suggested as a potential new
treatment option for advanced HCC, but the potential toxicities of
this form of immunotherapy are still largely unknown.29 There is still
an urgent need for improved, less toxic local agents for long-term
HCC control. Therefore, the aim of this study was to investigate the
potential of oncolytic Ld0-GFP as a new therapeutic agent against
HCC.
Our study focused on developing a novel OV for HCC by
enhancing the antitumor activities of an ICP0-null oncolytic
HSV-1 (Ld0-GFP) in HCC cells. Of the 11 HCC cells tested, we
found Ld0-GFP to be the most potent at killing in HCC cells. Sur-
prisingly, the enhanced oncolysis is only restricted in HCC cells,
but not in normal liver cell lines. Ld0-GFP showed a greater anti-
tumor effect than d0-GFP but had less toxicities on normal cell
lines. This agrees with published observations that show that the
continuous adaptation of a virus in specific cell lines at a high
MOI can result in a greater anti-cancer effect.30,31 Due to the adap-
tation of Ld0-GFP in HCC cells, the majority of HCC cell lines
studied were susceptible to direct oncolysis by Ld0-GFP. Ld0-
GFP kills tumor cells efficiently and directly through both replica-
tion and cell membrane fusion. These two cytolytic mechanisms
may also produce a synergistic effect through syncytial formation
that facilitates the spread of the OV in tumor tissue as well as
bystander killing of uninfected tumor cells.32–34
We sequenced the whole genomes of both d0-GFP and Ld0-GFP,
and the amino acids of all open reading frames (ORFs) in the virus
genome were compared (Table S1). Ld0-GFP had two vital syncy-
tial mutations, gKsyn1 (Ala-to-Val at position 40) and gB (Glu-to-
Asp at postion 816), which were reported to participate directly in
the fusion of HSV-1-infected cells.30,35–37 Other nonlethal muta-
tions in the UL9, UL12, and UL13 genes were also observed,
but not reported to participate directly in the fusion of HSV-1-in-
fected cells, which may play a role in enhanced cell-killing ability
of Ld0-GFP in HCC cells. Specifically, syncytial mutations that
cause extensive virus-induced cell fusion can arise in at least two
of the glycoproteins: glycoprotein K (gK) and glycoprotein B
(gB).30,37 Because the gB and gK are late genes of which the
expressions are dependent on viral DNA replication, an OV car-
rying these syncytial mutations will maintain the safety of the orig-
inal virus, because syncytial formation will only occur in replica-
tion-permissive tumor cells, but not in replication-restricted
normal nondividing cells.33 We hypothesized that Ld0-GFP may
be modified on viral glycoproteins to increase the cell-killing abilityines
cted with Ld0-GFP or d0-GFP at MOIs of 0.1, 1, and 10 PFU/cell for 24 h by using
endent experiments. (C) Determination of the level of ATP in the supernatants of four
10 PFU/cell for 24 h. (D) Determination of the level of HMGB1 in the supernatants of
, and 10 PFU/cell for 24 h. Graphs represent pooled data from three independent
as means ± SEM. Data were analyzed by unpaired two-tailed Student’s t tests.
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Figure 5. Neurovirulence Evaluation of Ld0-GFP in
BALB/c Mice
(A) Treatment scheme. i.c., intracerebral. BALB/c mice
were injected with KOS, d0-GFP, and Ld0-GFP viruses at
the indicated dosage and followed for survival. (B) Survival
analysis of BALB/c mice after treatment. (C) H&E staining
of whole brains from vehicle-, KOS-, d0-GFP-, and Ld0-
GFP-injected mice on day 1, 5, 15, and 30 following virus
injection. Red box represents injured areas. Scale bars,
200 mm. Data for survival were analyzed by the log-rank
(Mantel-Cox) test. All values are presented as the mean ±
SEM. ****p < 0.0001.
Molecular Therapy: Oncolyticsin HCC cells, but not in normal hepatic cells, by introducing some
syncytial mutations gK/A40V and gB/E816D, although the under-
lying mechanisms were not fully understood in this study.
In addition to the direct cytotoxic effect of OVs, it is also well recog-
nized that the antitumor immunity of OVs may play a vital role in
controlling tumor growth. It was reported that oncolytic adenovirus
and herpes virus can induce the oncolysis of the cancer cells and
make them release damage-associated molecular patterns (DAMPs)
to induce innate immune response within the tumor, remodeling
the tumor microenvironment from immunosuppressive to immune
active.38 Understanding the immunogenicity of dying or dead cancer
cells induced by OVs is important when considering their potency
for cancer immunotherapy.39 Our study revealed that ICD was the
primary death pattern induced by Ld0-GFP in HCC cells. Ld0-GFP
possessed much higher capability to induce ICD than d0-GFP. To
determine whether this Ld0-GFP-induced cell death was in fact
immunogenic, the in vitro characteristics of ICD in HCC cells were
investigated. Two type of DAMPs, released ATP and HMGB1, have
been significantly induced after Ld0-GFP infection. Moreover, Ld0-
GFP possessed much higher capability to release ICD determinants
than d0-GFP. The importance of ICD for initiating an antitumor
response has previously been demonstrated, so Ld0-GFP may have
better potency to initiate an antitumor response by inducing ICD.40
In vivo, we demonstrated that virotherapy was more effective at pro-
moting tumor regression in the subcutaneous xenograft model, syn-
geneic HCC mouse model, and orthotopic HCC model. As expected,160 Molecular Therapy: Oncolytics Vol. 15 December 2019intratumoral injection of Ld0-GFP exerted su-
perior therapeutic effects on the HCC xeno-
grafts implanted on the nude mice and immu-
nocompetent mice. We speculated that more
active cell-killing capability of OV and
enhanced immunogenic cell death may lead to
better tumor regression. Although the correla-
tion of oncolytic HSV replication/killing
in vitrowith antitumor activity in immunocom-
petent models has been challenged,41,42 we
believe that direct killing activity of OVs,
magnitude of immunogenic cell death to release
DAMPs, and initiation or augmentation of ahost antitumor immune response should all play an essential role
in oncolytic virotherapy. Moreover, intravenous injection of Ld0-
GFP significantly prolonged the overall survival in the orthotopic
HCC model, and the efficacy of Ld0-GFP systemic infusion is better
than that of d0-GFP systemic infusion, thus demonstrating that
Ld0-GFP may be amenable to systemic administration, thereby tar-
geting metastatic disease. Overall, these data indicated that Ld0-
GFP could be more effective as a single agent for both local and sys-
temic treatments of HCC.43
A preliminary systemic toxicity assessment was conducted in BALB/c
mice following intravenous injection of Ld0-GFP at a single high dose
(5  107 PFU). Neither illness nor significant body weight loss was
observed in the Ld0-GFP-treated and d0-GFP-treated groups, while
the illness and significant body weight loss was observed in the
KOS-treated group. Acute lung injury was found in KOS-injected
mice, but not in Ld0-GFP-injected mice and d0-GFP-injected mice
by histological analysis on days 1, 5, and 7 post-injection. Neurovir-
ulence evaluation results showed that Ld0-GFP had similar neurovir-
ulence similar to d0-GFP, both of them showing significantly lower
neurovirulence than KOS. All these data demonstrate that Ld0-GFP
possesses a safety profile with less toxicity and neurovirulence.44
Following the success of immune checkpoint inhibition in multiple
solid tumors, there are numerous trials evaluating the role of anti-
PD-1 agents in HCC.45,46 Given the limited response rate (18%) in
the management of advanced HCC, there is still an urgent need to
create new strategies to maximize the potential of anti-PD-1
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Figure 6. Systematic Toxicity Evaluation of Ld0-GFP
in BALB/c Mice
(A) Treatment scheme. i.v., intravenous. BALB/c mice
were injected with KOS, d0-GFP, and Ld0-GFP viruses at
the indicated dosage and followed for survival. (B) Body
weight monitoring of BALB/c mice after receiving a single
dose of 5  107 PFU viruses through i.v. injection. Scale
bars, 100 mm. (C) H&E staining of representative tissue
sections from vehicle-, KOS-, d0-GFP-, and Ld0-GFP-
injected mice on days 1, 5, 7, and 30 following virus in-
jection. Black arrows represent lung injuries. The statis-
tical significance of the intergroup comparisons of body
weight was analyzed using a repeated-measure ANOVA.
All values are presented as themean ± SEM. ***p < 0.001.
www.moleculartherapy.orgimmunotherapy. The development of OVs as novel immune sensi-
tizers has recently accelerated; the most notable example is T-Vec,
which helps overcome resistance to anti-PD-1 antibodies in patients
with advanced melanoma, therefore promoting intratumoral T cell
infiltration and improving anti-PD-1 immunotherapy. We are
currently exploring the use of multiple sensitizers, including small
molecular inhibitors and immune checkpoint antibodies,47 to facili-
tate the effectiveness of Ld0-GFP.
In summary, this study developed a novel HSV-1 vector, Ld0-GFP,
showing the increased tumor selectivity and improved oncolysis capa-
bility against HCC, which depends on efficient and selective viral repli-
cation and cancer cell killing in HCC cells. Furthermore, the utility of
Ld0-GFP as a potent anti-cancer agent was demonstrated by its poten-
tial to elicit cell apoptosis and several ICD-related DAMPs. In addi-
tion, Ld0-GFP is efficacious in three preclinical tumor models by
systemic infusion or intratumoral injection, and it is relatively safe
for the mice treated by systemic infusion or intracerebral injection.
The findings from this study have provided the rationale for the appli-
cation of a novel OV in treating HCC. The antitumor potential of Ld0-
GFP may be potentially enhanced by sequential administration or co-
administration of other agents to increase virus spread and replication,
as well as in combination with immune checkpoint inhibitors.48
MATERIALS AND METHODS
Cells
Huh7, SMMC7721, QGY7703, L-02, BEL7404, GSG7701, HCCLM3,
MHHC97H, H22, and HCT116 were purchased from the ChinaMolecular TheInfrastructure of Cell Line Resources (Beijing,
China). HepG2, Hep3B, U-2 OS, SK-HEP-1,
PLC/PRF/5, and H1299 were purchased from
the American Type Culture Collection (Mana-
ssas, VA, USA). U-2 OS, Huh7, HepG2,
Hep3B, SK-HEP-1, PLC/PRF/5, HCT116, and
H1299 were cultured in DMEM supplemented
with 10% (v/v) fetal bovine serum (FBS) (Invi-
trogen, CA, USA). SMMC7721, L-02,
BEL7404, QGY7703, GSG7701, HCCLM3,
MHHC97H, and H22 were cultured in 1640supplemented with 10% (v/v) FBS (Invitrogen, CA, USA). All cells
were maintained at 37C and 5% CO2.
Viruses and Virus Generation
Ld0-GFP used in this study is based on the d0-GFP virus, which was
generated as described previously in our laboratory.24 The d0-GFP vi-
rus was bearing the EGFP reporter genes under the control of the
human cytomegalovirus promoter replacing the viral ICP0 genes.
Ld0-GFP was produced by continuous passage of d0-GFP in three
HCC cells (Hep3B, QGY7703, and SMMC7721) until the fusogenic
plaques were observed. For every round of d0-GFP passage, these
three HCC cancer cell lines were sequentially infected with viruses
at an MOI of 1 and then harvested at 72 h post-infection for subse-
quent re-infection. Each HCC cell line was infected at least twice. Af-
ter seven rounds of repeated infection, the harvested viruses were
subjected to two rounds of freeze and thaw cycles and serially diluted
for infection of U-2 OS monolayers. After three passages of plaque
purification in cell culture, the EGFP reporter genes and plaques
with fusogenic feature were used to select and isolate the random
mutant viruses.
Ten fusogenic d0-GFP progenies were picked out and evaluated by
testing the replication difference and cell-killing percentages on
both HCC cell lines (QGY7703) and the hepatic normal cell line
(L-02). For the replication efficiency assay, the U-2 OS cells were in-
fected with d0-GFP or d0-GFP progenies at an MOI of 0.05 PFU.
After 72 h of infection, the infected cells together with the superna-
tants were collected and thereafter subjected to virus titration. Forrapy: Oncolytics Vol. 15 December 2019 161
A B
C D E
Figure 7. Oncolytic Efficacy of Ld0-GFP in the
Subcutaneous Xenograft Model Bearing Human
HCC
(A) Treatment scheme. s.c., subcutaneous. (B) Growth of
vehicle-, d0-GFP- or Ld0-GFP-treated Huh7 xenografts
in nude mice (n = 8). (C) Body weight of the treated nude
mice was monitored in the subcutaneous Huh7 xenograft
model. (D) Growth of vehicle-, d0-GFP- or Ld0-GFP-
treated Hep3B xenografts in nude mice (n = 8). (E) Body
weight of the treated nude mice was monitored in the
subcutaneous Hep3B xenograft model. The statistical
significance of the intergroup comparisons of tumor vol-
umes or body weight was analyzed using a repeated-
measure ANOVA. All values are presented as the mean ±
SEM. *p < 0.05, **p < 0.01, ns, not significant.
Molecular Therapy: Oncolyticsthe cell-killing ability assay, cells were infected with d0-GFP or d0-
GFP progenies at an MOI of 0.001–10 PFU/cell. After 72 h of infec-
tion, the number of viable cells was counted by the trypan blue
exclusion method. Finally, a novel virus (d0-GFP-7, named Ld0-
GFP) with relatively higher replication efficiency in U-2 OS and the
highest cell-killing activity in HCC cells (QGY7703), but not in liver
normal cells (L-02), was obtained. The IC50 was interpreted and
calculated by non-linear, dose-response regression analysis.
Virus Titration
The titers of the amplified viruses were determined on U-2 OS
monolayers using a classical plaque assay. In brief, a monolayer of
U-2 OS cells at a density of 2  106 cells per 6-cm dish was infected
with serially diluted virus in a volume of 0.5 mL for 1.25 h. After viral
entry, the cells were overlaid with 2% methylcellulose medium and
incubated at 37C in 5% CO2 for 2 days. Then, the dishes were
stained with neutral red overnight, and the plaques were counted
manually using a white-light transilluminator (Qilinbeier, China).
Viral titers (PFU/mL) were calculated using the equation plaque
numbers  dilution fold  2.
Virus Replication Assay
Cells were seeded in 6-cm plates at 106 cells/dish and infected with
Ld0-GFP (0.05 PFU/cell) or mock infected (10% DMEM). For
each time point, the infected cells were either harvested and there-
after subjected to virus titration or examined by fluorescence
microscopy.
Evaluation of the Size of Virus Plaques
To determine the plaque size from the various viruses assayed,
SMMC7721 monolayers were infected with diluted d0-GFP and
Ld0-GFP viruses in 2% methylcellulose medium. After 48 h of162 Molecular Therapy: Oncolytics Vol. 15 December 2019infection, the dishes were stained with me-
dium containing 0.01% neutral red overnight,
and the visualized virus plaques were photo-
graphed. The size of the plaques was
measured with a millimeter scale using ImageJ
software, and the area for comparison wascalculated using the following formula: area = (p)  (radius of
the minor axis)  (radius of the largest axis).
Cell-Killing Assay
Cells were seeded in 6-well plates at 1  106 cells/well and infected
with d0-GFP or Ld0-GFP at various MOIs of 0.001–10 PFU. For
each time point, cell viability was expressed as the percentage of
viable cells, which were counted by the trypan blue exclusion
method. The IC50 values were interpreted and calculated as previ-
ously described.
Cell Death Assay
Cells were infected with d0-GFP or Ld0-GFP atMOIs of 0.1, 1, and 10
PFU/cell or with mock (10%DMEM). After 24 h of infection, the cells
were harvested and stained with annexin V, Pacific Blue flow cytom-
etry kit (Invitrogen, CA, USA) and PI. Apoptotic cell death was deter-
mined by FACS analysis using the BD FACSDiva Software on a
FACSAria II cell sorter (Becton Dickinson, NJ, USA). ELISA analysis
was used to determine the expression of ICD determinants in the
supernatants of treated cells. Cells were infected with d0-GFP or
Ld0-GFP at MOIs of 0.1, 1, and 10 PFU/cell and mock (10%
DMEM). After 24 h of infection, the supernatants were harvested.
The released ATP was measured by an ATPlite Luminescence kit
(PerkinElmer, MA, USA), and the HMGB1 was measured by an
HMGB1 ELISA kit (Tecan, Switzerland).
Animal Experiments
The use of the mice was approved by the Institutional Animal Care
and Use Committee at Xiamen University (XMULAC20150016).
All mice were purchased from Shanghai Slack Laboratory Animal,
and they were housed under specific-pathogen-free conditions in a
chamber with controlled temperature and humidity.
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Figure 8. Oncolytic Efficacy of Ld0-GFP in Syngeneic HCC Mouse Models
(A) Treatment scheme. i.v., intravenous. (B) Growth of vehicle-, d0-GFP-, or Ld0-GFP-treated H22 tumors in immunocompetent BALB/c mice (n = 8). (C) Long-term survival
of BALB/c mice bearing H22 tumors. (D) Long-term survival in orthotopic HCC model bearing mouse H22 HCC in situ, after receiving three i.v. treatments of Ld0-GFP (1 
107 PFU) or vehicle (n = 8). (E) Representative images of livers from each group on days 10 and 20 following virus i.v. injection. Dashed black lines represent tumor areas. The
statistical significance of the intergroup comparisons of tumor volumes or body weight was analyzed using a repeated-measure ANOVA. Data for survival were analyzed by
the log-rank (Mantel-Cox) test. All values are presented as the mean ± SEM. *p < 0.05, **p < 0.01; ns, not significant.
www.moleculartherapy.orgSubcutaneous Xenograft Model
An inoculum of 1  106 Huh7 or 5  106 Hep3B cells was injected
subcutaneously into the flank of 5-week-old female BALB/c nu/nu
mice in 50 mL sterile PBS. After 20 or 14 days, Huh7 tumors or
Hep3B tumors reached an average size of100 mm3. Mice were ran-
domized into treatment groups immediately prior to treatment. Virus
(5  106 PFU) or vehicle (saline) was administered via intratumoral
injection every 3 days for three consecutive dosages in total. Tumor
growth and body weight were monitored every 3 days. At 21 days
after the last treatment, mice received their final measurements,
and the volume was calculated according to the following formula:
(length  width2)/2.
Syngeneic HCC Model
An inoculum of 106 murine HCC cells (H22) was injected subcuta-
neously into the flank of 6-week-old female BALB/c mice in 50 mL
sterile PBS. Mice were randomized into treatment groups on day 7
following tumor inoculation, immediately before treatment. Virus
(1  107 PFU) or vehicle (saline) was administered via intravenous
injection every 3 days for three consecutive dosages in total. Tumor
growth and body weight were monitored every 3 days, and the vol-
ume was calculated according to the following formula: (length width2)/2. The overall survival of mice was monitored over a 150-
day period.Orthotopic HCC Model
An inoculum of 5 105 murine HCC cells (H22) was implanted into
the left liver lobe of 6-week-old female BALB/c mice in 20 mL sterile
PBS. After 5 days, the mice were randomized into treatment groups
immediately before treatment. Virus (1 107 PFU) or vehicle (saline)
was administered by tail vein injection every 3 days for three consec-
utive dosages in total. The overall survival of mice wasmonitored over
a 100-day period. Representative images of livers in Ld0-GFP- and
d0-GFP-treated mice were taken 10 and 20 days after the initial
treatment.Neurovirulence Study
The 5-week-old female BALB/c mice were randomly assigned to four
groups of 18 mice each; mice were anesthetized with sodium thio-
pental (60 mg/kg) and inoculated with vehicle (saline), KOS, d0-
GFP, and Ld0-GFP by intracerebral injection into the left frontal
lobe of the brain, in a volume of 5 mL at a depth of 4.5 mm from
the skull surface over a period of 10 min. Ten mice of each groupMolecular Therapy: Oncolytics Vol. 15 December 2019 163
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following inoculation. For each time point (at 1, 5, 15, and 30 days
post-injection), two mice of each group were examined for histology
analysis. Paraffin sections (5 mm thick) of brain of BALB/c mice were
stained with H&E.
Systemic Toxicity Study
The 6-week-old female BALB/c mice were randomly assigned to four
groups of 18 mice each; mice were inoculated with vehicle (saline),
KOS, d0-GFP, and Ld0-GFP by intravenous injection into the tail
vein at a dose of 5  107 PFU in a volume of 500 mL over a period
of 2 min. Ten mice of each group were monitored for weights and
examined for histology analysis at 1, 5, 7, and 30 days post-injection.
Paraffin sections (5 mm thick) of vital tissues (including heart, liver,
spleen, lung, and kidney) of BALB/c mice (two mice for each group)
were stained with H&E.
Genome Sequencing
d0-GFP and Ld0-GFP genomic DNA were isolated from infected U-2
OS cells using standard protocols.49 An unpaired 350-bp Illumina li-
brary was generated and double-end sequenced using the HiSeq
sequencing platform (Novogene). The resulting reads were assembled
initially into large contigs. All ORFs in the virus genome were
compared between d0-GFP and Ld0-GFP, using KOS genome
sequence (GenBank: JQ673480) as a reference.
Statistics
Statistical significance was calculated using the unpaired two-tailed
Student’s t test (if the values follow normal distribution) or a
repeated-measure ANOVA, as indicated in the figure legends. Data
for survival was analyzed by the log-rank (Mantel-Cox) test. For all
statistical analyses, differences were considered significant when a p
value was below or equal to 0.05 (*p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001; ns, not significant). Statistical analyses
were performed using GraphPad Prism 7. The numbers of animals
included in the study are labeled in each figure.
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